Get the Stockscreener App
26.87
0.07%
0.02
Staar Surgical Co stock is traded at $26.87, with a volume of 592.89K.
It is up +0.07% in the last 24 hours and down -1.79% over the past month.
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
See More
Previous Close:
$26.85
Open:
$26.91
24h Volume:
592.89K
Relative Volume:
0.39
Market Cap:
$1.33B
Revenue:
$224.45M
Net Income/Loss:
$-95.27M
P/E Ratio:
-13.92
EPS:
-1.93
Net Cash Flow:
$-43.74M
1W Performance:
+1.21%
1M Performance:
-1.79%
6M Performance:
+52.41%
1Y Performance:
-27.67%
1-Day Range:
$26.85
$27.22
1-Week Range:
$26.55
$27.22
52-Week Range:
$13.50
$36.88
Staar Surgical Co Stock (STAA) Company Profile
Name
Staar Surgical Co
Sector
Industry
Phone
(626) 303-7902
Address
1911 WALKER AVE, MONROVIA, CA
Compare STAA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STAA
Staar Surgical Co
|
26.87 | 1.33B | 224.45M | -95.27M | -43.74M | -1.93 |
|
ISRG
Intuitive Surgical Inc
|
447.23 | 157.45B | 9.15B | 2.63B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
187.17 | 52.74B | 21.39B | 1.61B | 2.55B | 5.56 |
|
RMD
Resmed Inc
|
273.73 | 39.69B | 5.15B | 1.40B | 1.65B | 9.51 |
|
ALC
Alcon Inc
|
74.51 | 36.64B | 10.03B | 1.07B | 1.39B | 2.17 |
|
WST
West Pharmaceutical Services Inc
|
262.33 | 18.72B | 2.96B | 487.70M | 344.00M | 6.68 |
Staar Surgical Co Stock (STAA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | Wells Fargo | Equal Weight |
| Feb-12-25 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-12-25 | Downgrade | Jefferies | Buy → Hold |
| Feb-12-25 | Downgrade | Mizuho | Outperform → Neutral |
| Feb-12-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-15-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-11-24 | Upgrade | BTIG Research | Neutral → Buy |
| Mar-11-24 | Upgrade | Stifel | Hold → Buy |
| Dec-05-23 | Downgrade | Needham | Buy → Hold |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-15-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-03-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jun-07-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-17-23 | Initiated | Piper Sandler | Neutral |
| Feb-06-23 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-28-22 | Reiterated | BTIG Research | Buy |
| Dec-08-22 | Initiated | Stifel | Hold |
| Nov-07-22 | Upgrade | Sidoti | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Apr-08-22 | Initiated | Needham | Buy |
| Mar-28-22 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jul-09-21 | Initiated | Oppenheimer | Perform |
| Jan-19-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Oct-26-20 | Downgrade | Sidoti | Buy → Neutral |
| Aug-31-20 | Upgrade | Sidoti | Neutral → Buy |
| Aug-06-20 | Reiterated | The Benchmark Company | Buy |
| Jul-06-20 | Downgrade | Sidoti | Buy → Neutral |
| Jun-24-20 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-15-20 | Initiated | Jefferies | Buy |
| Dec-04-19 | Initiated | BTIG Research | Buy |
| Sep-24-18 | Reiterated | The Benchmark Company | Buy |
| Aug-06-18 | Resumed | The Benchmark Company | Buy |
| Nov-20-17 | Reiterated | The Benchmark Company | Buy |
| Aug-14-17 | Reiterated | The Benchmark Company | Buy |
| Mar-03-17 | Reiterated | The Benchmark Company | Buy |
| May-18-16 | Upgrade | The Benchmark Company | Hold → Buy |
| Sep-10-13 | Resumed | The Benchmark Company | Buy |
| Feb-28-13 | Reiterated | The Benchmark Company | Buy |
| Nov-01-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-02-12 | Initiated | Northland Securities | Outperform |
| Oct-25-11 | Reiterated | The Benchmark Company | Buy |
| Oct-12-10 | Initiated | Morgan Joseph | Buy |
| May-11-10 | Initiated | Benchmark | Buy |
View All
Staar Surgical Co Stock (STAA) Latest News
Combining price and volume data for STAAR Surgical CompanyTrade Analysis Report & Community Consensus Trade Alerts - newser.com
Alcon, STAAR Surgical see US antitrust waiting period expire - MLex
Alcon and STAAR Surgical Announce Expiration of Hart-Scott-Rodino Waiting Period for Alcon’s Acquisition of STAAR - MarketScreener
$1.5B Eye Care Merger Progresses: Alcon's Premium Buyout of STAAR Surgical Clears Key Regulatory Hurdle - Stock Titan
Broadwood files definitive proxy, STAAR reaffirms Alcon merger - Investing.com
Broadwood files definitive proxy, STAAR reaffirms Alcon merger By Investing.com - Investing.com UK
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAA and CYBR on Behalf of Shareholders - Benzinga
Alcon: Seeing Is Believing As Buyout Of STAAR Surgical Hangs In Balance (NYSE:ALC) - Seeking Alpha
Yunqi Capital Ltd Increases Stake in Staar Surgical Co - GuruFocus
Key deals this week: STAAR Surgical, Pfizer, DB Insurance, Strive, Rocket Lab and more (PFE:NYSE) - Seeking Alpha
Gwangju Shinsegae Eye Clinic Selected as Best ICL Center for 2 Consecutive Years - 아시아경제
Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors - MSN
STAAR Surgical (STAA) Proposes $28 All-Cash Merger with Alcon - GuruFocus
59% Premium at $28 Per Share: STAAR Surgical Board Champions Alcon Merger as China Sales Decline Continues - Stock Titan
Assenagon Asset Management S.A. Acquires 111,686 Shares of STAAR Surgical Company $STAA - MarketBeat
Alcon’s Deal For STAAR Surgical Faces Pushback From Major Shareholder - Finimize
Intraocular Lens Market Size, Share, Growth, & Demand | Industry Report 2033 - Straits Research
STAAR Surgical (NASDAQ:STAA) Shares Pass Above 200-Day Moving AverageWhat's Next? - MarketBeat
Alcon AG stock hits 52-week low at $74.83 By Investing.com - Investing.com South Africa
Broadwood opposes Alcon’s acquisition of STAAR Surgical By Investing.com - Investing.com South Africa
STAAR SHAREHOLDER ALERT: Kaskela Law LLC Investigates - GlobeNewswire
Broadwood opposes Alcon’s acquisition of STAAR Surgical - Investing.com
Broadwood Partners (27.5% Owner) Opposes STAAR's $28/Share Alcon Deal | STAA Stock News - Stock Titan
STAAR Surgical’s Shareholder Yunqi Capital Opposes Proposed Merger With Alcon – Here’s Why - Stocktwits
Shareholder Rebellion Intensifies as Staar Surgical Acquisition Reaches Critical Juncture - AD HOC NEWS
STAAR draws no rival bids as Yunqi joins Broadwood against Alcon deal - Investing.com Nigeria
STAAR confirms no competing bids emerged during Alcon merger window By Investing.com - Investing.com Australia
Yunqi Capital opposes STAAR Surgical’s merger with Alcon By Investing.com - Investing.com South Africa
Staar has no competing bids, another shareholder rejects Alcon buy - BioWorld MedTech
STAAR confirms no competing bids emerged during Alcon merger window - Investing.com
Major shareholder Yunqi Capital to vote against Staar Surgical 's proposed sale to Alcon - MSN
Alcon’s Staar Surgical acquisition clears hurdle as ‘window shop’ period closes - MassDevice
51% Premium Deal Stands: STAAR's $28/Share Alcon Merger Remains Unchallenged After 45-Day Shop Period - Stock Titan
Yunqi Capital Opposes Staar Surgical (STAA) Sale to Alcon - GuruFocus
Yunqi Capital opposes STAAR Surgical’s merger with Alcon - Investing.com
Staar Surgical urges shareholders to back Alcon merger as “window shop” period ends (STAA:NASDAQ) - Seeking Alpha
Yunqi Capital, 5.1% Holder and One of STAAR Surgical Company’s Largest Shareholders, Announces Intention to Vote Against the Proposed Sale to Alcon - Bluefield Daily Telegraph
$28 vs Previous $55 Offer: Major STAAR Surgical Investor Yunqi Capital Fights Against 'Undervalued' Alcon Deal - Stock Titan
STAAR SURGICAL CO. STOCKHOLDER NOTICE: Kaskela Law LLC Announces Investigation of STAAR Surgical Company (NASDAQ: STAA) Proposed Stockholder Buyout and Encourages Long-Term Investors to Contact the Firm - ACCESS Newswire
STAAR Surgical Company (NASDAQ:STAA) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Alcon to Buy Staar for $1.5 Billion in Vision Surgery Expansion - MSN
Daily Brief Australia: Alcidion, D3 Energy, Percheron Therapeutics and more - Smartkarma
European Commission grants marketing authorisation to aflibercept biosimilar EYLUXVI (ALT-L9) - Ophthalmology Times Europe
Is STAAR Surgical Poised for a Turnaround After Mixed Earnings in 2025? - Yahoo Finance
Pinnacle Investment Management Ltd Invests $1.16 Million in STAAR Surgical Company $STAA - MarketBeat
Staar Surgical’s board urges stockholders to approve Alcon acquisition in face of scrutiny - MassDevice
51% Premium: Medical Device Leader Alcon to Acquire STAAR Surgical in Premium Cash Deal Worth $28 Per Share - Stock Titan
Cataract Devices Market Estimated at USD 14.68 Billion in 2025 | - openPR.com
Dr. Jason Brinton Selected as Principal Investigator for Landmark FDA Study Demonstrating Superior Safety and Efficacy of EVO ICL Technology - columbiadailyherald.com
Staar Surgical Co Stock (STAA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.91%
1.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):